EORTC protocol 08092 - MAPPING

Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy.
Trial StatusRecruiting
DatesDate of activation: 18-Jul-11
Data management at EORTCFull
Phase3
Randomized trialYes
Type-
Targeted Sample sizeEORTC Groups: 587 - All Groups: 587
Number of steps2
DrugPazopanib
Blind trial medication
Study StaffMary O'Brien (Study Coordinator) - Royal Marsden Hospital - Sutton, Surrey, Sutton
Baktiar Hasan (Statistician) - EORTC Headquarters, Brussels
Marlies Dictus (Data Manager) - EORTC Headquarters, Brussels
Athanasios Pallis (Coordinating Physician) - EORTC Headquarters, Brussels
Benedicte Marchal (Project Manager) - EORTC Headquarters, Brussels, benedicte.marchal( at )eortc.be, +32 27741078
Gloria Montanes (Clinical Research Associate) - EORTC Headquarters, Brussels
Type of cancerLung
Participating GroupsEORTC Lung Cancer Group(Coordinating Group)
Centers authorized by EORTC Clinique Andre Renard (Herstal, Belgium) - Inst. 9428
Universitair Ziekenhuis Gent (Gent, Belgium) - Inst. 104
Centre Hospitalier Regional De La Citadelle (Liege, Belgium) - Inst. 145
Clinique et Maternité Sainte Elisabeth (Namur, Belgium) - Inst. 1201
National Cancer Institute (Cairo, Egypt) - Inst. 8000
UniversitaetsMedizin Mannheim (Mannheim, Germany) - Inst. 527
Klinik Loewenstein (Loewenstein, Germany) - Inst. 9032
University General Hospital Heraklion (Heraklion, Greece) - Inst. 3610
University Clinic Golnik (Golnik, Slovenia) - Inst. 7650
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, The Netherlands) - Inst. 301
Isala Klinieken - Locatie Weezenlanden (Zwolle, The Netherlands) - Inst. 329
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital (Sheffield, United Kingdom) - Inst. 609
Christie NHS Foundation Trust (Manchester, United Kingdom) - Inst. 610
Royal Marsden Hospital - Chelsea, London (London, United Kingdom) - Inst. 613
Royal Marsden Hospital - Sutton, Surrey (Sutton, United Kingdom) - Inst. 616
Guy's and St Thomas' NHS - Guy's Hospital (London, United Kingdom) - Inst. 625
NHS Lothian - Western General Hospital (Edinburgh, United Kingdom) - Inst. 641
NHS Grampian - Aberdeen Royal Infirmary (Aberdeen, United Kingdom) - Inst. 642
King's Mill Hospital (Sutton-in-Ashfield, Nottinghamshire, United Kingdom) - Inst. 9063
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom) - Inst. 6982
Nottingham University Hospitals NHS Trust - City Hospital campus (Nottingham, United Kingdom) - Inst. 6998
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT01208064
EudraCT2010-018566-23
Protocol documents in PDF
(requires password)
Study documentation
Back to Protocol section